Benchmark Research Recognized as Best Clinical Trial Site at The 2012 Vaccine Industry Excellence Awards

Benchmark Research’s Austin, Texas location has been recognized as Best Clinical Trial Site at the 2012 Vaccine Industry Excellence (ViE) Awards, held during the Annual World Vaccine Congress.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
“Having two Benchmark Research sites considered for the inaugural Best Clinical Trial Site category is a testament to the efforts of the entire Benchmark team." Mark Lacy, Co-Founder and CEO of Benchmark Research

Austin, TX (PRWEB) April 24, 2012

Benchmark Research’s Austin, Texas location has been recognized as Best Clinical Trial Site at the 2012 Vaccine Industry Excellence (ViE) Awards, held during the Annual World Vaccine Congress. Benchmark Research is a network of therapeutically diverse, dedicated multi-therapeutic research centers that specializes in vaccine research. The panel of judges specifically commended Benchmark Research Austin for exceeding enrollment timelines for all studies, as well as being the first site to complete enrollment in three of the seven trials within the judging period.

“Having two Benchmark Research sites considered for the inaugural Best Clinical Trial Site category is a testament to the efforts of the entire Benchmark team, not only those nominated sites. I am very proud of what each of our sites accomplished over the last year, and I'm especially honored to have Austin recognized as the top site in this category,” said Mark Lacy, Co-Founder and CEO of Benchmark Research. “It is truly an honor for Benchmark Research to be recognized as Best Clinical Trial Site. We have committed substantial time and resources in developing our specialty as industry-leading vaccine sites, and being recognized with this ViE award represents a culmination of those efforts,” added Scott Barrett, Co-Founder and COO of Benchmark Research.

Benchmark Research offers its clients access to nearly 60,000 patients in our research database, as well as nearly 16 million potential patients in three states: Sacramento and San Francisco, California; New Orleans, Louisiana; and Austin, Fort Worth, and San Angelo, Texas. Benchmark’s geographic and demographic diversity allows us to meet and exceed enrollment projections on many of the trials we support. We currently work with more than 40 Principal Investigators across all locations and support all therapeutic areas, with the exception of Oncology.
For more information about how Benchmark Research can help you accomplish and accelerate your study goals, please contact:

Andrew Kimball
Director of Research and Development
(469) 854-0294
andrewkimball(at)benchmarkresearch(dot)net


Contact

  • Andrew Kimball
    andrewkimball@benchmarkresearch.net
    469-854-0294
    Email